Annals of Surgical Oncology

, Volume 21, Issue 13, pp 4270–4277 | Cite as

The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients

  • Li-Han Lin
  • Ming-Wei Lin
  • Kwei Mar
  • Chun-Shu Lin
  • Dar-Der Ji
  • Wei-Ping Lee
  • Herng-Sheng Lee
  • Ming-Fang Cheng
  • Kan-Tai Hsia
Head and Neck Oncology



The aim of this study was to investigate the impact of hMLH1 polymorphisms on treatment outcomes in patients with oral squamous cell carcinoma (OSCC).


Genotypings were performed by direct DNA sequencing in peripheral blood leukocytes from 185 male OSCC patients. Patients received primary surgery with or without adjuvant radiotherapy. Two hMLH1 tag single nucleotide polymorphisms (SNPs)—rs1800734 (−93G>A in the promoter) and rs1540354 (in the third intron)—were chosen from the HapMap project. Overall survival (OS) and disease-free survival (DFS) were compared between different genotypes.


The hMLH1 rs1800734 and rs1540354 polymorphisms were in weak linkage disequilibrium (r2 = 0.456). OSCC patients with the rs1800734 AA genotype had a significantly poor prognosis in both OS and DFS. This SNP can also predict the outcomes of OSCC patients with postoperative adjuvant radiotherapy, especially in advanced stage; however, no significant differences in patient outcomes were found for the hMLH1 rs1540354 genotypes.


Our results demonstrate that the hMLH1 −93G>A SNP is found to be associated with patient outcomes in OSCC. This SNP can also predict their treatment outcome of radiotherapy.



This study was supported by grants from the National Science Council NSC 99-2314-B-010-044-MY3, Aim for Top University plan from the Department of Education, Taiwan, and Department of Health, Taipei City Government 96001-62-015.

Conflict of interest


Supplementary material

10434_2014_3897_MOESM1_ESM.doc (50 kb)
Supplementary material 1 (DOC 49 kb)
10434_2014_3897_MOESM2_ESM.docx (16 kb)
Supplementary material 2 (DOCX 16 kb)
10434_2014_3897_MOESM3_ESM.docx (12 kb)
Supplementary material 3 (DOCX 16 kb)
10434_2014_3897_MOESM4_ESM.tif (1.4 mb)
Supplementary material 4 (TIFF 1445 kb)
10434_2014_3897_MOESM5_ESM.tif (1.1 mb)
Supplementary material 5 (TIFF 1128 kb)
10434_2014_3897_MOESM6_ESM.tif (1.1 mb)
Supplementary material 6 (TIFF 1119 kb)


  1. 1.
    Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 2009;15:388–399.PubMedCrossRefGoogle Scholar
  2. 2.
    Department of Health, Executive Yuan, Taiwan, ROC. Cancer registry annual report in Taiwan area. Department of Health; 2012.Google Scholar
  3. 3.
    Kademani D, Bell RB, Bagheri S, et al. Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg. 2005;63:1599–1605.PubMedCrossRefGoogle Scholar
  4. 4.
    da Silva SD, Ferlito A, Takes RP, et al. Advances and applications of oral cancer basic research. Oral Oncol. 2011;47:783–791.PubMedCrossRefGoogle Scholar
  5. 5.
    Shah JP, Gil Z. Current concepts in management of oral cancer: surgery. Oral Oncol. 2009;45:394–401.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000;36:256–263.PubMedCrossRefGoogle Scholar
  7. 7.
    Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7:335–346.PubMedCrossRefGoogle Scholar
  8. 8.
    Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev. 2008;129:391–407.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008;29:673–680.PubMedCrossRefGoogle Scholar
  10. 10.
    Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene. 2003;22:2352–2360.PubMedCrossRefGoogle Scholar
  11. 11.
    Murata H, Khattar NH, Kang Y, Gu L, Li GM. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene. 2002;21:5696–5703.PubMedCrossRefGoogle Scholar
  12. 12.
    Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology. 2005;129:537–549.PubMedGoogle Scholar
  13. 13.
    Bannister LA, Waldman BC, Waldman AS. Modulation of error-prone double-strand break repair in mammalian chromosomes by DNA mismatch repair protein Mlh1. DNA Repair (Amst). 2004;3:465–474.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhang Y, Rohde LH, Emami K, et al. Suppressed expression of non-DSB repair genes inhibits gamma-radiation-induced cytogenetic repair and cell cycle arrest. DNA Repair (Amst). 2008;7:1835–1845.PubMedCrossRefGoogle Scholar
  15. 15.
    Yan T, Seo Y, Kinsella TJ. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells. Clin Cancer Res. 2009;15:6912–6920.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Lipkin SM, Rozek LS, Rennert G, et al. The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nat Genet. 2004;36:694–699.PubMedCrossRefGoogle Scholar
  17. 17.
    Allan JM, Shorto J, Adlard J, et al. MLH1 −93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer. 2008;123:2456–2459.PubMedCrossRefGoogle Scholar
  18. 18.
    Mrkonjic M, Roslin NM, Greenwood CM, et al. Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer. PLoS One. 2010;5(10):e13314.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Chen H, Taylor NP, Sotamaa KM, et al. Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer. 2007;120:1684–1688.PubMedCrossRefGoogle Scholar
  20. 20.
    Samowitz WS, Curtin K, Wolff RK, et al. The MLH1 −93G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosomes Cancer. 2008;47:835–844.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Shih CM, Chen CY, Lee IH, Kao WT, Wang YC. A polymorphism in the hMLH1 gene (−93G>A) associated with lung cancer susceptibility and prognosis. Int J Mol Med. 2010;25:165–170.PubMedGoogle Scholar
  22. 22.
    Edge SB, American joint committee on cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  23. 23.
    Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res. 1987;95:229–249.PubMedGoogle Scholar
  24. 24.
    Huang SH, Chang PY, Liu CJ, Lin MW, Hsia KT. O6-methylguanine-DNA methyltransferase gene coding region polymorphisms and oral cancer risk. J Oral Pathol Med. 2010;39:645–650.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhao JH. 2LD, GENECOUNTING and HAP: Computer programs for linkage disequilibrium analysis. Bioinformatics. 2004;20:1325–1326.PubMedCrossRefGoogle Scholar
  26. 26.
    Raptis S, Mrkonjic M, Green RC, et al. MLH1 −93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst. 2007;99:463–474.PubMedCrossRefGoogle Scholar
  27. 27.
    Whiffin N, Broderick P, Lubbe SJ, et al. MLH1−93G>A is a risk factor for MSI colorectal cancer. Carcinogenesis. 2011;32:1157–1161.PubMedCrossRefGoogle Scholar
  28. 28.
    Czerninski R, Krichevsky S, Ashhab Y, Gazit D, Patel V, Ben-Yehuda D. Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma. Oral Dis. 2009;15:206–213.PubMedCrossRefGoogle Scholar
  29. 29.
    Gonzalez-Ramirez I, Ramirez-Amador V, Irigoyen-Camacho ME, et al. hMLH1 promoter methylation is an early event in oral cancer. Oral Oncol. 2011;47:22–26.PubMedCrossRefGoogle Scholar
  30. 30.
    Arita M, Zhong X, Min Z, Hemmi H, Shimatake H. Multiple sites required for expression in 5′-flanking region of the hMLH1 gene. Gene. 2003;306:57–65.PubMedCrossRefGoogle Scholar
  31. 31.
    Mei M, Liu D, Dong S, Ingvarsson S, Goodfellow PJ, Chen H. The MLH1 −93G promoter variant influences gene expression. Cancer Epidemiol. 2010;34:93–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–316.PubMedCrossRefGoogle Scholar
  33. 33.
    Sanguansin S, Petmitr S, Punyarit P, Vorasubin V, Weerapradist W, Surarit R. HMSH2 gene alterations associated with recurrence of oral squamous cell carcinoma. J Exp Clin Cancer Res. 2006;25:251–257.PubMedGoogle Scholar
  34. 34.
    Lo YL, Hsiao CF, Jou YS, et al. Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer. 2010;72:280–286.PubMedCrossRefGoogle Scholar
  35. 35.
    Park SH, Lee GY, Jeon HS, et al. −93G>A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer. 2004;112:678–682.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Li-Han Lin
    • 1
  • Ming-Wei Lin
    • 2
  • Kwei Mar
    • 3
  • Chun-Shu Lin
    • 4
  • Dar-Der Ji
    • 5
  • Wei-Ping Lee
    • 6
    • 7
  • Herng-Sheng Lee
    • 8
  • Ming-Fang Cheng
    • 1
    • 8
    • 9
  • Kan-Tai Hsia
    • 1
  1. 1.Institute of Oral Biology, School of DentistryNational Yang-Ming UniversityTaipeiTaiwan
  2. 2.Institute of Public HealthNational Yang-Ming UniversityTaipeiTaiwan
  3. 3.Department of Dentistry, Zhongxiao BranchTaipei City HospitalTaipeiTaiwan
  4. 4.Department of Radiation Oncology, Tri-Service General HospitalNational Defense Medical CenterTaipeiTaiwan
  5. 5.Department of Tropical MedicineNational Yang-Ming UniversityTaipeiTaiwan
  6. 6.Institute of Biochemistry and Molecular BiologyNational Yang-Ming UniversityTaipeiTaiwan
  7. 7.Division of Gastroenterology, Department of MedicineTaipei Veterans General HospitalTaipeiTaiwan
  8. 8.Department of Pathology, Tri-Service General HospitalNational Defense Medical CenterTaipeiTaiwan
  9. 9.Division of Laboratory MedicineHualien Armed Forces General HospitalHualienTaiwan

Personalised recommendations